Vir Biotechnology, Inc. (VIR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-10

Key Insights

Mark Eisner, the Chief Medical Officer of Vir Biotechnology, is stepping down from his role effective April 24, 2026, indicating a leadership change at the company.
The company has initiated a search for Eisner's successor, suggesting the need to find a new medical leader to guide the company's drug development efforts.
As a key executive departure, this event could impact the company's operations and pipeline progress, warranting close monitoring by investors.

Insider Trading Filed: 2026-04-07

Key Insights

Marianne De Backer, the President and CEO of Vir Biotechnology, Inc., has sold 72,559 shares of the company's common stock, likely to satisfy tax withholding obligations related to the vesting of restricted stock units.
The reporting person also indirectly owns 53,118 shares of Vir Biotechnology through the Ureel-De Backer Family Trust, of which she and her spouse are trustees.
The sale of shares by the CEO, while routine for tax purposes, may be viewed as a neutral signal by investors as it does not represent a discretionary trade.

Insider Trading Filed: 2026-03-24

Key Insights

Insider Brent Sabatini, SVP and Chief Accounting Officer, sold 7,711 shares of Vir Biotechnology, Inc. (VIR) on March 23, 2026 at an average price of $9.12 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan that Sabatini had adopted on December 19, 2025, indicating the transaction was pre-planned.
Following the sale, Sabatini continues to hold 61,902 shares of Vir Biotechnology, demonstrating he still maintains a significant equity stake in the company.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.